HC Wainwright Issues Negative Estimate for BioNTech Earnings

BioNTech SE Sponsored ADR (NASDAQ:BNTX) – HC Wainwright cut their Q1 2026 EPS estimates for BioNTech in a research report issued on Tuesday, March 31st. HC Wainwright analyst R. Burns now anticipates that the company will earn ($2.41) per share for the quarter, down from their previous estimate of ($2.27). HC Wainwright has a “Buy” rating and a $130.00 price target on the stock. The consensus estimate for BioNTech’s current full-year earnings is ($3.88) per share. HC Wainwright also issued estimates for BioNTech’s Q2 2026 earnings at ($2.43) EPS, Q3 2026 earnings at $0.69 EPS, Q4 2026 earnings at ($0.42) EPS and FY2026 earnings at ($4.57) EPS.

A number of other research analysts have also recently commented on the company. BMO Capital Markets dropped their price target on BioNTech from $143.00 to $128.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 11th. Citigroup reduced their target price on BioNTech from $145.00 to $130.00 and set a “buy” rating for the company in a report on Wednesday, March 11th. Morgan Stanley decreased their price target on BioNTech from $134.00 to $125.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 10th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of BioNTech in a research report on Tuesday, March 17th. Finally, Wall Street Zen cut shares of BioNTech from a “hold” rating to a “sell” rating in a research report on Saturday, March 14th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $133.07.

BioNTech Trading Up 0.6%

Shares of BNTX stock opened at $89.42 on Thursday. BioNTech has a 12-month low of $79.52 and a 12-month high of $124.00. The company has a quick ratio of 7.49, a current ratio of 7.54 and a debt-to-equity ratio of 0.01. The company has a 50 day moving average of $102.32 and a 200-day moving average of $101.33. The firm has a market cap of $22.47 billion, a P/E ratio of -17.06 and a beta of 1.51.

Institutional Trading of BioNTech

Hedge funds have recently made changes to their positions in the stock. Dodge & Cox lifted its stake in shares of BioNTech by 315.7% in the third quarter. Dodge & Cox now owns 3,647,091 shares of the company’s stock worth $359,676,000 after buying an additional 2,769,654 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of BioNTech by 43.0% during the 4th quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company’s stock valued at $150,235,000 after buying an additional 474,796 shares during the period. GSK plc bought a new position in BioNTech in the fourth quarter valued at about $84,711,000. Invesco Ltd. increased its stake in BioNTech by 5.6% in the 2nd quarter. Invesco Ltd. now owns 681,100 shares of the company’s stock worth $72,517,000 after buying an additional 35,958 shares in the last quarter. Finally, Morgan Stanley raised its holdings in BioNTech by 12.9% during the fourth quarter. Morgan Stanley now owns 680,669 shares of the company’s stock valued at $64,800,000 after acquiring an additional 77,653 shares during the period. 15.52% of the stock is owned by institutional investors.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.